We use cookies and other technologies on this website to enhance your user experience.
By clicking any link on this page you are giving your consent to our Privacy Policy and Cookies Policy.

Over ID-ODS Adult

ID - ODS Adult, uw volgende stap dichter bij gepersonaliseerde geneeskunde (tm)

Individually Designed Optimum Dosing Strategies, or ID – ODS, is a simulation resource tool with extensive model library built from population pharmacokinetic models published in high quality, peer reviewed literature. The application is designed to aid health care professionals in the optimal dosing and continuous therapeutic monitoring of medications at the bedside. Enter all clinically relevant information through a user friendly interface to generate priori dosing regimens or to supply concentration data for posteriori dose adjustments in the adult patient population via Monte Carlo simulation and individual pharmacokinetic parameter optimization via Bayesian feedback.

Wat is er nieuw in de nieuwste versie 2.7.0

Last updated on Apr 23, 2019

2.7: New settings
2.6: PK target, user-defined dosing regiments
2.5 Amoxicillin, Flucloxacillin
2.4: patients tab
2.3: Vanco AUC calc
2.2: conventional & SI units
2.0: new UI
0.1.18: Telavancin, Tigecycline
0.1.17: Ceftriaxone, Levofloxacin, Polymyxin
0.1.16: Doripenem
0.1.14: Daptomycin
0.1.10: Ciprofloxacin
0.1.9: Meropenem
0.1.8: Pip. and Tazo.
0.1.7: Ceftazidime
0.1.6: MyDose
0.1.3: Vancomycin
0.1.2: Aminoglycoside
0.1.0: Three commonly used antibiotics

Vertaling Laden...

Aanvullende APP -informatie

Laatste Versie

Verzoek update van ID-ODS Adult 2.7.0

Geüpload door

سهيل رجباني

Android vereist

Android 4.1+

Meer Info

ID-ODS Adult Screenshots

Abonneer u op APKPure
Wees de eerste die toegang krijgt tot de vroege release, nieuws en gidsen van de beste Android -games en apps.
Nee bedankt
Aanmelden
Succesvol ingeschreven!
Je bent nu geabonneerd op APKPure.
Abonneer u op APKPure
Wees de eerste die toegang krijgt tot de vroege release, nieuws en gidsen van de beste Android -games en apps.
Nee bedankt
Aanmelden
Succes!
Je bent nu geabonneerd op onze nieuwsbrief.